An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers

Phase 1

Completed

• Conditions: Pharmacokinetics

• Registration Number: NCT00721448
• Lead Sponsor: AstraZeneca

Brief Summary

This will be a single centre study conducted at the 3rd hospital affiliated to Peking University. Approximately 24 healthy Chinese volunteers, male and female, will be recruited to obtain at least 20 evaluable volunteers. The primary objective of this study is to characterize the pharmacokinetics of AZD6140 and its active metabolite AR-C124910XX after single and multiple (twice daily) doses of AZD6140 90 mg and 180 mg in healthy Chinese volunteers. The secondary objective of this study is to determine the safety and tolerability of single and multiple (twice daily) 90 mg and 180 mg doses of AZD6140 by physical examination, clinical laboratory tests, vital signs, and collection of adverse events in healthy Chinese volunteers.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2008-07-22
• Study First Submitted QC: 2008-07-23
• Study First Posted: 2008-07-24
• Primary Completion: 2008-08
• Study Completion: 2008-08
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-02
• Last Update Posted: 2010-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Chinese ethnicity defined as having both parents and 4 grandparents who are Chinese
• Have a normal Body size and weigh at least 50 kg

Read More

Exclusion Criteria

• History of diseases or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs determined by the investigator
• Current and/or past history of intolerance or hypersensitivity to drugs with a similar chemical structure or mechanism of action to AZD6140 or any ingredient in its formulation
• Symptoms of any clinically significant illness within 2 weeks of screening
• A personal or family history of bleeding diatheses or a reasonable suspicion of vascular abnormalities including aneurysms

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
AZD6140 and AR-C124910XX concentration	-2,0,0.5,1,2,3,4,6,8,12,18,24,36,48,72 hours on days 4,5,6,7,8and 9. Day 10 the samples are at the specified timeframes (0,0.5,1,2,3,4,6,8,12,18,24,36,48,72 hours)

Secondary Outcome Measures

Name	Time	Method
determine the safety and tolerability of single and multiple doses of AZD6140 by physical examination, clinical laboratory tests, vital signs, and collection of adverse events	day -1, 4, 7, 10, 13+3~5

Trial Locations

Locations (1)

Research Site; 🇨🇳 Beijing, China